Unknown

Dataset Information

0

Gene Expression Profile in the Sandhoff Mouse Brain with Progression of Age.


ABSTRACT: Sandhoff disease (SD) is a fatal neurodegenerative disorder belonging to the family of diseases called GM2 Gangliosidosis. There is no curative treatment of SD. The molecular pathogenesis of SD is still unclear though it is clear that the pathology initiates with the build-up of ganglioside followed by microglial activation, inflammation, demyelination and apoptosis, leading to massive neuronal loss. In this article, we explored the expression profile of selected immune and myelination associated transcripts (Wfdc17, Ccl3, Lyz2, Fa2h, Mog and Ugt8a) at 5-, 10- and 16-weeks, representing young, pre-symptomatic and late stages of the SD mice. We found that immune system related genes (Wfdc17, Ccl3, Lyz2) are significantly upregulated by several fold at all ages in Hexb-KO mice relative to Hexb-het mice, while the difference in the expression levels of myelination related genes is not statistically significant. There is an age-dependent significant increase in expression of microglial/pro-inflammatory genes, from 5-weeks to the near humane end-point, i.e., 16-week time point; while the expression of those genes involved in myelination decreases slightly or remains unchanged. Future studies warrant use of new high-throughput gene expression modalities (such as 10X genomics) to delineate the underlying pathogenesis in SD by detecting gene expression changes in specific neuronal cell types and thus, paving the way for rational and precise therapeutic modalities.

SUBMITTER: Singh K 

PROVIDER: S-EPMC9690576 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene Expression Profile in the Sandhoff Mouse Brain with Progression of Age.

Singh Kshitiz K   Quinville Brianna M BM   Mitchell Melissa M   Chen Zhilin Z   Walia Jagdeep S JS  

Genes 20221103 11


Sandhoff disease (SD) is a fatal neurodegenerative disorder belonging to the family of diseases called GM2 Gangliosidosis. There is no curative treatment of SD. The molecular pathogenesis of SD is still unclear though it is clear that the pathology initiates with the build-up of ganglioside followed by microglial activation, inflammation, demyelination and apoptosis, leading to massive neuronal loss. In this article, we explored the expression profile of selected immune and myelination associate  ...[more]

Similar Datasets

| S-EPMC3032697 | biostudies-literature
| S-EPMC3843766 | biostudies-literature
| S-EPMC7238384 | biostudies-literature
| S-EPMC5561971 | biostudies-literature
| S-EPMC3633415 | biostudies-literature
| S-EPMC3585940 | biostudies-literature
| S-EPMC5866022 | biostudies-literature
| S-EPMC3155528 | biostudies-literature
| S-EPMC2637985 | biostudies-literature
| S-EPMC3777910 | biostudies-literature